Benefits
LDL oxidation 20% reduction 6-month trial (Carmeli & Fogelman 2009)
Carmeli E, Fogelman Y 2009 — clinical trial in 19 healthy subjects. 250 mg/day glabridin oral administration for 6 MONTHS. RESULTS: PLASMA LDL OXIDATION DECREASED 20% vs baseline. Foundational atheroprotective evidence — LDL oxidation is key step in atherogenesis. Mechanism: glabridin antioxidant + LDL particle protection. Long-duration trial (6 months) provides robust evidence.
Type 2 diabetes 12-week trial (Hattori 2019)
Hattori et al. 2019 — 12-WEEK clinical trial in 10 patients with TYPE 2 DIABETES. Glabridin 300 mg/day vs placebo. RESULTS: REDUCED levels of TOTAL CHOLESTEROL, LDL-CHOLESTEROL, GLYCATED HEMOGLOBIN, IMMUNOREACTIVE GLUCAGON, and BODY FAT COMPOSITION. Multi-target metabolic + lipid benefits in diabetes population. Smaller sample but compelling clinical condition relevance. Important T2D adjunct evidence.
Metabolic syndrome 12-week trial (Panda 2017)
Panda et al. 2017 — 12-WEEK clinical trial in 50 patients with METABOLIC SYNDROME. GLFO 300 mg/day vs placebo. RESULTS: NORMALIZED body weight, BMI, visceral fat, AND HDL-cholesterol content. Multi-domain metabolic syndrome reversal. Larger sample (n=50) strengthens evidence. Important metabolic syndrome adjunct evidence.
Skin lightening + hyperpigmentation (multiple cosmetic studies)
Glabridin INHIBITS UVB-induced PIGMENTATION + TYROSINASE — disrupts melanin pathway. In vitro: 16× MORE POTENT than HYDROQUINONE for skin lightening (established skin-lightening pharmaceutical). Single-center double-blind clinical study of 18 subjects with hydroquinone-free formula containing glabridin showed SIGNIFICANT REDUCTIONS in UV-induced hyperpigmentation vs negative control AND vs 4% hydroquinone cream. Foundational topical/oral skin lightening evidence.
Anti-atherogenic activity (mechanism + clinical)
Glabridin is the most ABUNDANT and POTENT antioxidant constituent toward LDL oxidation among 7 constituents isolated from licorice (Vaya et al., Belinky et al.). Protective effect on LDL oxidation confirmed in animals AND humans. Mechanism: ring-B hydroxyl group critical for antioxidant activity (2'-hydroxyl most important per structure-activity relationship studies).
Anti-inflammatory effects (broad)
Glabridin shows broad ANTI-INFLAMMATORY effects across multiple cell types and inflammatory contexts. Mechanism: NF-κB pathway suppression + inflammatory cytokine reduction. Mechanism for systemic and topical anti-inflammatory applications.
Antimicrobial activity (foundational)
Glabridin was FIRST ISOLATED while searching for ANTIMICROBIAL AGENT in licorice root by bioassay-directed fractionation. Foundational characterization. Mechanism: antimicrobial activity against various organisms — relevant to oral/skin applications.
Mechanism of action
LDL oxidation inhibition (primary atheroprotective mechanism)
Glabridin INHIBITS LDL OXIDATION via direct antioxidant activity. Ring-B 2'-hydroxyl most critical per structure-activity. Most ABUNDANT and POTENT antioxidant among 7 licorice constituents toward LDL oxidation. Foundation atheroprotective mechanism.
Tyrosinase inhibition (skin lightening mechanism)
INHIBITS TYROSINASE — rate-limiting enzyme in melanin synthesis. 16× more potent than hydroquinone in vitro (vs established skin-lightening pharmaceutical). Mechanism for skin lightening + hyperpigmentation reduction applications.
AMPK activation (metabolic mechanism)
Activates AMPK (AMP-activated protein kinase) — energy sensing pathway. Stimulates fatty acid oxidation. Mice studies: glabridin-containing licorice flavonoid oil increased muscle GLUT4 translocation via AMPK. Mechanism for metabolic/glucose effects.
Anti-inflammatory NF-κB pathway suppression
Suppresses NF-κB activation + reduces inflammatory cytokines. Mechanism for systemic anti-inflammatory effects + topical anti-inflammatory applications.
Estrogen receptor binding (mild phytoestrogenic)
Mild estrogen receptor binding as isoflavonoid. Mechanism for some hormonal-related applications + caution in hormone-sensitive conditions.
Antimicrobial activity
First isolated as antimicrobial agent from licorice. Activity against various organisms supporting topical/oral applications.
Low oral bioavailability (~7.5%) — DELIVERY LIMITATION
Critical pharmacokinetic limitation: glabridin oral bioavailability only ~7.5%. Mechanism: rapid first-pass metabolism + low intestinal absorption. Branded Glavonoid® delivery system (in MCT oil) enhances bioavailability significantly vs purified glabridin.
Clinical trials
Clinical trial (Carmeli E, Fogelman Y 2009).
19 healthy subjects. Oral glabridin 250 mg/day for 6 MONTHS.
PLASMA LDL OXIDATION DECREASED 20% vs baseline. Foundational atheroprotective evidence — LDL oxidation is key step in atherogenesis. 6-month trial duration provides robust long-term evidence. Smaller sample limits statistical power but clear directional effect.
Clinical trial (Hattori 2019).
10 patients with TYPE 2 DIABETES. Glabridin 300 mg/day vs placebo for 12 weeks. Multiple metabolic + lipid markers measured.
REDUCED levels of TOTAL CHOLESTEROL, LDL-CHOLESTEROL, GLYCATED HEMOGLOBIN, IMMUNOREACTIVE GLUCAGON, AND BODY FAT COMPOSITION. Multi-target T2D-relevant benefits in single intervention. Smaller sample but compelling diabetes population evidence.
Clinical trial (Panda et al. 2017).
50 patients with METABOLIC SYNDROME. GLFO 300 mg/day vs placebo for 12 weeks. Body weight, BMI, visceral fat, HDL-cholesterol measured.
NORMALIZED body weight, BMI, visceral fat, AND HDL-cholesterol content. Multi-domain metabolic syndrome reversal. Larger sample (n=50) strengthens evidence base. Foundational metabolic syndrome clinical evidence.
About this ingredient
GLABRIDIN is an ISOFLAVONOID specific to GLYCYRRHIZA GLABRA L. (licorice root) — distinct from GLYCYRRHIZIN (the pseudoaldosteronism-causing fraction) and the most studied licorice flavonoid. While the existing Glavonoid® entry in NutraSmarts focuses on the BRANDED MCT-oil delivery system from Kaneka Corporation, this entry focuses on GLABRIDIN as the specific isoflavonoid bioactive. Glabridin is located in CORK LAYER + DECAYED PARTS of licorice roots. STABILITY influenced by temperature, pH, light, humidity (best stored dry, dark, low oxygen, neutral pH). FIRST ISOLATED while searching for antimicrobial agent in licorice root by bioassay-directed fractionation (foundational characterization). Most ABUNDANT and POTENT antioxidant among 7 constituents isolated from licorice toward LDL oxidation (Vaya et al., Belinky et al.). CLINICAL EVIDENCE: CARMELI & FOGELMAN 2009 PIVOTAL 6-MONTH TRIAL in 19 healthy subjects at 250 mg/day — PLASMA LDL OXIDATION DECREASED 20%. HATTORI 2019 12-WEEK trial in 10 T2D patients at 300 mg/day — REDUCED total cholesterol, LDL-cholesterol, glycated hemoglobin, immunoreactive glucagon, body fat composition. PANDA 2017 12-WEEK trial in 50 metabolic syndrome patients at 300 mg/day — NORMALIZED body weight, BMI, visceral fat, HDL-cholesterol. SKIN LIGHTENING applications: 16× MORE POTENT than HYDROQUINONE in vitro for tyrosinase inhibition. Single-center double-blind clinical study of 18 subjects with hydroquinone-free formula containing glabridin showed significant reductions in UV-induced hyperpigmentation vs both negative control AND 4% hydroquinone cream. Multiple Asian cosmeceutical research applications.
MECHANISMS: LDL oxidation inhibition (primary atheroprotective — ring-B 2'-hydroxyl critical per structure-activity); tyrosinase inhibition (skin lightening — 16× hydroquinone potency); AMPK activation (metabolic — fatty acid oxidation + GLUT4 translocation); NF-κB anti-inflammatory pathway; mild estrogen receptor binding (phytoestrogenic — caution in hormone-sensitive conditions); antimicrobial activity.
CRITICAL LIMITATION: oral bioavailability only ~7.5% — branded delivery systems (Glavonoid® MCT oil from Kaneka) significantly enhance bioavailability vs purified glabridin. EVIDENCE: 2/5 reflects: (1) CARMELI 2009 PIVOTAL 6-MONTH LDL oxidation trial with 20% reduction, (2) HATTORI 2019 T2D 12-week multi-target metabolic trial, (3) PANDA 2017 METABOLIC SYNDROME 12-week n=50 trial with multi-domain normalization, (4) MULTIPLE SKIN LIGHTENING clinical studies + 16× hydroquinone in vitro potency, (5) WELL-CHARACTERIZED LDL oxidation + tyrosinase inhibition + AMPK mechanisms, (6) FOUNDATIONAL antimicrobial isolation history, (7) ABUNDANT + POTENT antioxidant among licorice constituents per structure-activity studies, (8) SMALL SAMPLE SIZES across most clinical trials limit definitive conclusions, (9) ~7.5% ORAL BIOAVAILABILITY LIMITATION — critical pharmacokinetic concern, (10) BRANDED DELIVERY (Glavonoid®) preferred over purified glabridin for systemic effects. SAFETY: Excellent — flavonoid fraction (no glycyrrhizin pseudoaldosteronism risk) + clinical trial safety record. Best positioned as: (a) ATHEROPROTECTIVE adjunct via LDL oxidation reduction (Carmeli 2009 evidence — clinically distinct from cholesterol-lowering mechanisms), (b) TYPE 2 DIABETES METABOLIC adjunct (Hattori 2019 multi-target evidence), (c) METABOLIC SYNDROME adjunct (Panda 2017 n=50 evidence), (d) SKIN LIGHTENING + HYPERPIGMENTATION topical/oral adjunct (16× hydroquinone potency), (e) NOT optimal as PURIFIED GLABRIDIN due to ~7.5% bioavailability — BRANDED GLAVONOID® MCT OIL DELIVERY preferred for systemic effects, (f) PREGNANCY: precautionary avoidance, (g) HORMONE-SENSITIVE conditions: caution (mild phytoestrogenic), (h) higher-evidence than typical 'licorice flavonoid' due to multiple specific glabridin trials + mechanism characterization. Honest framing: Glabridin has FOUNDATIONAL clinical evidence for LDL oxidation reduction (Carmeli 2009 6-month trial) + multi-target metabolic effects (Hattori 2019, Panda 2017) + skin lightening (16× hydroquinone potency). LIMITATION: oral bioavailability ~7.5% means PURIFIED GLABRIDIN supplements may not achieve clinical effects observed in research. BRANDED GLAVONOID® MCT-oil delivery system from Kaneka enhances bioavailability significantly — practical recommendation for those wanting glabridin systemic effects. Skin lightening applications well-supported via topical formulations (16× hydroquinone potency in vitro + clinical studies). LDL oxidation reduction mechanism is biochemically distinct from cholesterol-lowering — important atheroprotective adjunct framing. Sample sizes across clinical trials remain small (10-50 subjects) limiting definitive conclusions. Reasonable atheroprotective + metabolic + skin lightening adjunct based on evidence — particularly via Glavonoid® branded delivery system rather than purified glabridin.